As TXNIP has been considered a promising therapeutic target for diabetes 52, targeting TXNIP may be an ideal therapeutic strategy for patients with both NASH and diabetes. The gene discussed is TXNIP; the disease is metabolic dysfunction-associated steatohepatitis.